Helt rett FiloD
Fra 258.000 til 308.000
Mitt innlegg er korrigert
2 Likes
Kan vi vente oss en Asia-partner på GGK snart tro? Det nærmer seg et år siden Ludovic Robin og Amir Snapir startet sitt arbeid i PCIB, og begge to har GGK-studiet og FimaChem som hovedoppgave.
En mulig partner i Asia har vært tema under flere kvartalspresentasjoner, mest snakkesalig var vel Per på Q3 i november hvor han sa "we are working to see whether we can get a partner in for Asia, and that’s part of what the CBO, Ludovic Robin, is focusing on right now."
På Q4 nå i februar var han mer tilknappet, kanskje har man kommet så langt at han måtte veie ordene mer nøye?
Spennende blir det iallefall, jeg blir ikke forundret om det kommer en avtale med Takeda eller et annet Asiatisk selskap i løpet av en måned eller to.
17 Likes
Open access
Photochemical Internalization: Light Paves Way for New Cancer Chemotherapies and Vaccines
« Eighteen published papers described the pre-clinical and clinical developments of PCI-mediated delivery of chemotherapeutic agents or antigens. »
Mer data som underbygger novel teknologien i siste journal. Mye som bekreftes og styrkes bare på 1 år!
Litt morsomt at prof fra Japan ved navn Takeda har deltatt i forskningen 
« Curran emphasized that Takeda’s ambitions in gene therapy will require it to partner with academic leaders in the field, a playbook that it’s followed over the past three years as it’s worked to expand into cell therapy.
“In the cell space, there’s more innovation you can bring up into proof of principle milestones in academia,” said Andy Plump, Takeda’s head of R&D, in an interview.
———————-
Cell and gene therapy are part of what Takeda calls its “second wave” of R&D projects, a group of early-stage drugs and programs that it sees as progressing to regulatory stages by 2025 or later.
In the nearer term, the drugmaker is advancing a “first wave” of clinical candidates that it told investors will deliver 14 new molecular entities by 2024. Five of those will come in rare disease, with the others spread across oncology, neuroscience, gastro-enterology and vaccines.
“We think the cascade of news coming forward on these programs will transform how people view Takeda,” Curran said.
More importantly to the investors gathered in New York, Takeda expects these experimental drugs will eventually earn $10 billion in peak annual sales, which would represent a sizable addition to a business that generated $30 billion in sales last year.«
CONNECT Founding Partners: Her finnes flere store pharma selskap. Blant annet Takeda.
12 Likes
Venter stadig på et gjennombrudd for teknologien til PCIB, men tiden går uten at noe skjer.
Må innrømme at jeg blir litt matt etterhvert 
1 Like
Du griber det forkert an du må ligge de daglige forventninger fra dig se det i lidt større perspektiv.
Eller sælg og find en ny investering.
5 Likes
Stayerevnen din når det gjelder å skrive negative innlegg er imponerende Ebitor. Har du samme stayerevne som aksjonær tro? 
4 Likes
Vil du ha flere eksempler på at TTT i biotek (og at det kanskje ikke er for alle) og at det plutselig KAN komme gjennombrudd som ved mRNA generelt og som i Genmab , tok jo en evighet før det løsnet.
Tok bare 100 gangeren😅
7 Likes
Seneste oppdatering fra forskningssamarbeidspartner eTheRNA
// 11 MARCH 2021
eTheRNA extends leadership team with the appointment of Dr. Volker Germaschewski as Senior Vice President for R&D
Niel (Belgium)
eTheRNA immunotherapies NV (‘eTheRNA’ or ‘The Company’), a clinical-stage company developing immunotherapies from its proprietary mRNA TriMix platform for the treatment of cancer and infectious diseases, announced today that Dr. Volker Germaschewski has been appointed Senior Vice President for R&D. Volker joins eTheRNA from Kymab Ltd. (Cambridge, UK) where, over 10 years, he was initially Senior Director Discovery and subsequently Vice President of Haematology. Prior to that he held several positions in Biopharm R&D at GlaxoSmithKline.
“I am excited to join eTheRNA at this incredible time of unprecedented advances in mRNA technologies within vaccine and therapeutics development”, said Dr. Germaschewski. “I am looking forward to working with the team at eTheRNA and our partners and our collaborators as we accelerate development of our promising and innovative oncology and infectious disease technologies and products.”
The team strives to continuously improve
's mRNA immunotherapy platforms. The team focuses on the design, early stage evaluation and optimization of new mRNA therapies to fuel eTheRNA’s pipeline. Visit our website: [https://etherna.b](https://etherna.be
Så kom denne meldingen i dag 22. mars🤞
(https://mobile.twitter.com/eTheRNA_immuno/status/1373925526486851586)
Consortium led by
awarded
TIGER grant of EUR 6.9 million. The grant was awarded for the development of a mRNA cancer vaccine for treating HPV16+ cancers. Clinical trial to commence end of 2021. Read more: https://lnkd.in/efdGW5h
- Accelerate development of novel mRNA vaccine for hard-to-treat cancers
- Clinical trial to commence end of 2021
Niel (Belgium) eTheRNA immunotherapies NV (‘eTheRNA’), a clinical-stage company developing mRNA-based immunotherapies as off-the shelf products for the treatment of cancer and infectious diseases, announces the award of a TIGER grant of EUR 6.9 million from the EU commission. The grant was awarded to a consortium led by eTheRNA and will be used to accelerate the development of a novel, potentially best-in-class therapeutic mRNA cancer vaccine for treating recurrent/metastatic Human Papillomavirus strain 16 positive (HPV16+) cancers such as head and neck cancer, cervical cancer, anogenital cancer.
eTheRNA’s mission is to develop mRNA-based immunotherapies as off-the-shelf products for the treatment of cancer and infectious diseases through its next generation mRNA vaccines development platform and its in-house manufacturing. Head and neck squamous cell carcinomas (HNSCCs) are the sixth leading cause of cancer worldwide. Early data suggests mRNA may play a key role in treating cancers and autoimmune diseases with potential mRNA market of approx. $37bn in 2030.
The Phase I/IIa trial for the mRNA vaccine will be administered either as a stand-alone therapy or supplementary to PD-1 inhibitor standard of care. Safety, immunogenicity and clinical activity are the key endpoints of the clinical program. Biomarker and Patient Reported Outcome Measure (PROM) research conducted in parallel with the study will facilitate future, informed therapeutic and care decisions by both patients and care teams. The mRNA cancer vaccine will be optimized for intravenous (IV) administration.
Safety and efficacy of the IV mRNA lipid nanoparticle (LNP) product has already been demonstrated in preclinical development studies. Furthermore, eTheRNA has proven the safety and efficacy of its mRNA cancer vaccines in previous clinical trials, albeit with the mRNA vaccine delivered via different routes of administration.
Marina Cools, VP of Clinical Development at eTheRNA, commented : “eTheRNA and its collaborators welcome the award of this grant. In addition to HPV, this collaboration will investigate the possibility of applying mRNA technologies to the treatment of other cancer indications with poorly met medical needs.”
The consortium project encompasses essential elements for preparing therapy validation in later stage clinical studies while addressing patient needs, values and choices. Scale up of GMP-production using eTheRNA’s in-house manufacturing platform for IV mRNA vaccines will enable further clinical studies.
Så vet vi at PCIB tidligere er med i er konsortium for Bac med Amsterdam UMC. Amsterdam UMC er også med i TIGER grant konsortium over med blant annet eTheRNA.
https://www.maastrichtuniversity.nl/news/consortium-receives-€11-million-grant-fight-against-antibiotic-resistance
Hva tror du om dagens melding fra eTheRNA @lenny?
PCI Biotech fimavacc fase 1
: A phase I clinical study with fimaVacc has been performed in healthy volun- teers to study the safety and immunogenicity of this novel vaccine. The subjects were vaccinated with HPV16 E7 peptides and Keyhole Limpet Hemocyanin (KLH) protein, serving as model antigens for peptide- and protein-based vaccines. Both antigens were formulated with fimaporfin and the TLR3 agonist poly-ICLC (Hiltonol) and adminis- tered in up to three vaccinations.
Conclusion: The photochemically based fimaVacc vaccination technology can be applied safely in humans, and enhances T-cell responses to an HPV peptide vaccine over what is achieved in a control group which received antigen þ adjuvant without fimaVacc.
https://www.annalsofoncology.org/article/S0923-7534(20)34496-3/pdf
Og nu skal eTheRNA begynne (commense) kliniske studier end of 2021. Dette er spennende!
21 Likes
Tenker vi her at det er kombinasjonen LNP og Fimaporfin som er aktuell da eller?
Denne alenegangen til PCIB er ørkesløs. Kanskje det mest fornuftige var å få til en fusjon med det kommersialiserte PHO?
…men hvor kommer Pcib inn her?
Jeg ser det nevnes at de har bevist sikkerhet for andre levringsplatformer i prekliniske studier, men verken FimaNac eller fimavacc nevnes. Også BioNTec snakker om mrna-vaksiner mot kreft innen et par år. Heller ikke her nevnes Pcib.
Er årsaken til at Pcib ikke nevnes; at de rett og slett ikke er med på dette? Er vi iferd med å stå igjen på perrongen? Hadde vi vært med på dette skulle det da ikke vært børsmeldt?
Mange spørsmål fra meg. Er det noen som vet svarene, eller forklaringer på hvorfor Pcib ikke nevnes?
PCI Biotech and eTheRNA immunotherapies initiate research collaboration
Exploring synergies between PCI and TriMix technologies to further enhance the effect of novel oncologic therapies
Oslo (Norway) and Niel (Belgium), 8 December 2016 —PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, and eTheRNA immunotherapies NV, a VUB spin-off company backed by strong life science investors to continue the development of mRNA-based immunotherapies, today announced that they are initiating a preclinical research collaboration.
The partnership is governed by a preclinical research collaboration agreement. In brief, the collaborators will evaluate technology compatibility and synergy based on in vivo studies. The companies will evaluate results achieved from this research collaboration and then explore the potential for a further partnership.
Per Walday, CEO of PCI Biotech, said: “I’m very pleased to announce another research agreement in the field of nucleic acid therapeutics. We believe that the PCI technology has the potential to play a role in the realisation of several new therapeutic modalities. We look forward to explore synergies with eTheRNA’ s unique and innovative mRNA based TriMix technology. “
Dirk Reyn, CEO of eTheRNA immunotherapies, commented: “Encouraged by the impressive phase I/IIa study results with our ex vivo/cell version of our TriMix technology, we are focusing on the off-the shelf variant that can be applied intranodally, intradermally or by direct injection in the tumour and that represent a more convenient and cost effective product. While we are now about to initiate our second clinical trial with this in vivo formulation of TriMix, we continue to evaluate new technologies that may further enhance the efficacy of this mode of application. We are very pleased about the potential of the PCI platform and the opportunities of this research agreement.”
@Molla her kan ingen gi deg noen fasit nu på HVA som KAN bli fasiten. Men at det bør komme en avklaring innen kort tid avtale eller ei er vel rimelig klart kommunisert fra selskapet ved Vacc strategi. Og se uthevet tekst fra meldingen over. Avtalen har vært preklinisk (5 år varighet) og det bør ha kommet resultater fra dette samarbeidet nu. Skal det over i klinisk skal det meldes da det er endring.
Og som dagens melding fra eTheRNA sier nu skal eTheRNA begynne (commense) kliniske studier end of 2021. HVIS PCI Biotech skal delta her blir en mulig avtale børsmeldt.
Det kan ikke være langt unna en avklaring når PCI Biotech ved CEO nevner at en form for resultat fra Vacc kan komme i 2022. Avklaring på Vacc kan umulig være langt unna nu? Om det er eTheRNA eller noen helt andre biotechs det forhandles med kan selvsagt være en mulighet? Umulig å si med sikkerhet selvsagt. Men et langt forskningssamarbeid fra 2016 er kanskje mest nærliggende?
3 Likes
Ett farvel til Biontech, Ultimovacs og Astra Zeneca, holder opptimismen tilbake. Dette kan lede til flere gratisavtaler med nye partnere, foer de eventuellt om noen aar skal bestemme seg om de gaar videre. Uten release studiet, ville dette sett rimelig haaploest ut. Naa mangler det bare at det studiet misslykes ogsaa, saa staar vi paa bar bakke;-((
1 Like
Godt fundet jubel…
Der er ikke noget umiddelbart nævnt omkring PCIB, meeeeen kan det helt udelukkes, med tanke på dette…
Sikkerhet og effekt av IV mRNA lipid nanopartikkel (LNP) produkt har allerede blitt demonstrert i prekliniske utviklingsstudier. Videre har eTheRNA bevist sikkerheten og effekten av mRNA-kreftvaksinene i tidligere kliniske studier, om enn med mRNA-vaksinen levert via forskjellige administrasjonsveier.
1 Like
Det hadde selvsagt stått hvis PCI hadde blitt brukt i en klinisk studie.
Det begynner vel å HASTE med en avklaring? Regner med at søknad om å oppstart av studie på mennesker allerede i år er sendt, eller sendes når som helst. Der må det jo fremkomme hvilken leveringsteknologi de skal bruke. (I artikkelen vises det kun til Lipider, må innrømme at jeg frykter litt for Pcibs rolle i dette, - og eTeRNA er jo Pcibs siste samarbeidspartner på dette området.)
1 Like
Nei, eTheRNA er ikke eneste samarbeidspartner her!
@AndyO »Det hadde selvsagt stått hvis PCI hadde blitt brukt i en klinisk studie.»
Det er akkurat det som diskuteres eller spekuleres på her om eTheRNA og PCI Biotech KAN gå over i en klinisk kommersiell avtale! Hva er sannsynligheten 0-100%, umulig å si og noen har null tro, helt greit
Som sagt må en endring fra preklinisk til klinisk samarbeid børsmeldes. Det bør kunne forventes en avklaring på dette innen kort tid hva som blir realiteten. Det KAN ikke stå noe sted før en avtale eventuelt blir signert (da meldes avtale på klinisk) nu er samarbeidet PREKLINISK
1 Like
Ok, ser du har rett i det. Det er dog fare for at det tynnes i rekkene. Hva er grunnen til det. Virker ikke vacc og Nac så bra som Walday skal ha det til? Holder han oss for narr?
2 Likes